Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 12

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data

Authors Rock AE, Lerner J, Badowski ME

Received 8 April 2020

Accepted for publication 25 May 2020

Published 10 June 2020 Volume 2020:12 Pages 201—210

DOI https://doi.org/10.2147/HIV.S184018

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Bassel Sawaya


Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1

1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 60612, USA

Correspondence: Melissa E Badowski
University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, 833 S. Wood, Room164, MC886, Chicago, IL 60612, USA
Email Badowski@uic.edu

Abstract: The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evolve as data emerges on the potential for new combination therapy with the investigational agent, islatravir, as well as a potential strategy to minimize post-marketing safety concerns with recommended first-line agents, such as integrase inhibitors. The goal of this review is to assess recent and emerging data on the non-nucleoside reverse transcriptase inhibitor, doravirine.

Keywords: doravirine, HIV-1, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]